Havrix Monodose (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Monodose is indicated for the prevention of hepatitis A infection in various populations.

• Pre‑exposure prophylaxis for travelers to endemic areas.
• Routine immunization of children as part of national vaccination programs.
• Protection of individuals at occupational risk, such as laboratory workers.
• Outbreak control in communities with ongoing hepatitis A transmission.
• Post‑exposure prophylaxis for persons who have not previously been vaccinated, when administered promptly.
• Immunization of people with chronic liver disease who are at higher risk of severe hepatitis A.

Adverse reactions reported after Havrix Monodose are generally mild and transient.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Headache.
• Fatigue or malaise.
• Nausea.
• Mild muscle aches.

Serious

• Severe allergic reaction (anaphylaxis).
• Guillain‑Barré syndrome (rare).
• Thrombocytopenia.
• High‑grade fever persisting more than 48 hours.
• Neurologic symptoms such as weakness or paresthesia.
• Seizures (very rare).

Before administering Havrix Monodose, healthcare providers should consider several precautionary measures.

• Confirm no severe allergy to any vaccine component, especially gelatin or yeast proteins.
• Defer vaccination in individuals with acute moderate or severe illness until recovery.
• Use caution in persons with weakened immune systems; vaccine may be less effective.
• Pregnancy status should be assessed; vaccine is generally avoided unless benefits outweigh potential risks.
• Evaluate for history of thrombocytopenia or bleeding disorders before intramuscular injection.
• Ensure proper storage and handling to maintain vaccine potency.

Havrix Monodose has limited known drug interactions, but certain situations warrant attention.

Avoid

• Concomitant administration of live viral vaccines (e.g., measles‑mumps‑rubella) within 4 weeks, as immune response may be reduced.

Use with caution

• Immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may diminish antibody response.
• Antipyretics (acetaminophen, ibuprofen) taken prophylactically may mask fever, though they do not affect immunogenicity.
• Blood products given within 2 weeks may interfere with vaccine efficacy.
• Chronic liver disease medications may require timing adjustments.